Cathy J Bradley1, K Robin Yabroff, Joan L Warren, Christopher Zeruto, Neetu Chawla, Elizabeth B Lamont. 1. *Department of Health Systems, Management, and Policy, Colorado Comprehensive Cancer Center, University of Colorado, Aurora, CO †Health Services and Economics Branch, National Cancer Institute, Bethesda ‡Information Management Services, Rockville, MD §Departments of Medicine and Health Care Policy, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Little is known about the use and costs of antineoplastic regimens for elderly patients with metastatic colorectal cancer (mCRC). We report population-based trends over a 10-year period in the treatment, survival, and costs in mCRC patients, stratified by ages 65-74 and 75+. METHODS: We used Surveillance, Epidemiology, and End Results-Medicare data for persons diagnosed with metastatic colon (N=16117) or rectal cancer (N=4008) between 2000 and 2009. We estimated the adjusted percent of patients who received antineoplastic agents, by type, number, and their costs 12 months following diagnosis. We report the percent of patients who received 3 or more of commonly prescribed agents and estimate survival for the 24-month period following diagnosis by age and treatment. RESULTS: The percentage that received 3 or more agents increased from 3% to 73% in colon patients aged 65-74 and from 2% to 53% in patients 75+. Similar increases were observed in rectal patients. Average 1-year costs per patient in 2009 were $106,461 and $102,680 for colon and rectal cancers, respectively, reflecting an increase of 32% and 20%, for patients who received antineoplastic agents. Median survival increased by about 6 and 10 months, respectively, for colon and rectal patients aged 65-74 who received antineoplastic agents, but an improvement of only 1 month of median survival was observed for patients 75+. CONCLUSIONS: Expensive multiple agent regimens are increasingly used in older mCRC patients. For patients aged 64-75 years, these treatments may be associated with several months of additional life, but patients aged 75+ may incur considerable expense without any survival benefit.
BACKGROUND: Little is known about the use and costs of antineoplastic regimens for elderly patients with metastatic colorectal cancer (mCRC). We report population-based trends over a 10-year period in the treatment, survival, and costs in mCRC patients, stratified by ages 65-74 and 75+. METHODS: We used Surveillance, Epidemiology, and End Results-Medicare data for persons diagnosed with metastatic colon (N=16117) or rectal cancer (N=4008) between 2000 and 2009. We estimated the adjusted percent of patients who received antineoplastic agents, by type, number, and their costs 12 months following diagnosis. We report the percent of patients who received 3 or more of commonly prescribed agents and estimate survival for the 24-month period following diagnosis by age and treatment. RESULTS: The percentage that received 3 or more agents increased from 3% to 73% in colonpatients aged 65-74 and from 2% to 53% in patients 75+. Similar increases were observed in rectal patients. Average 1-year costs per patient in 2009 were $106,461 and $102,680 for colon and rectal cancers, respectively, reflecting an increase of 32% and 20%, for patients who received antineoplastic agents. Median survival increased by about 6 and 10 months, respectively, for colon and rectal patients aged 65-74 who received antineoplastic agents, but an improvement of only 1 month of median survival was observed for patients 75+. CONCLUSIONS: Expensive multiple agent regimens are increasingly used in older mCRC patients. For patients aged 64-75 years, these treatments may be associated with several months of additional life, but patients aged 75+ may incur considerable expense without any survival benefit.
Authors: Cathy J Bradley; K Robin Yabroff; Joan L Warren; Christopher Zeruto; Neetu Chawla; Elizabeth B Lamont Journal: Med Care Date: 2017-01 Impact factor: 2.983
Authors: Angela B Mariotto; Joan L Warren; Chris Zeruto; Diarmuid Coughlan; Michael J Barrett; Lirong Zhao; K Robin Yabroff Journal: J Natl Cancer Inst Monogr Date: 2020-05-01
Authors: Clara J K Lam; Lindsey Enewold; Timothy S McNeel; Dolly P White; Joan L Warren; Angela B Mariotto Journal: J Natl Cancer Inst Monogr Date: 2020-05-01
Authors: K Robin Yabroff; Jingxuan Zhao; Janet S de Moor; Helmneh M Sineshaw; Andrew N Freedman; Zhiyuan Zheng; Xuesong Han; Ashish Rai; Carrie N Klabunde Journal: J Natl Cancer Inst Date: 2020-05-01 Impact factor: 13.506
Authors: Cheryl K Altice; Matthew P Banegas; Reginald D Tucker-Seeley; K Robin Yabroff Journal: J Natl Cancer Inst Date: 2016-10-20 Impact factor: 13.506
Authors: Angela B Mariotto; Lindsey Enewold; Jingxuan Zhao; Christopher A Zeruto; K Robin Yabroff Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-10 Impact factor: 4.090
Authors: Janet S de Moor; Michelle Mollica; Annie Sampson; Brenda Adjei; Sallie J Weaver; Ann M Geiger; Barnett S Kramer; Emily Grenen; Memi Miscally; Henry P Ciolino Journal: JNCI Cancer Spectr Date: 2021-04-09